These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8052342)

  • 1. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
    Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
    Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
    Arends J; Willms BH
    Horm Metab Res; 1986 Nov; 18(11):761-4. PubMed ID: 3539737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
    Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
    Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
    Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
    Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
    Fehmann HC
    MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
    [No Abstract]   [Full Text] [Related]  

  • 6. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB; Taylor R
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Miglitol for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
    Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
    S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
    Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
    Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
    Carlson RF
    Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
    Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Middle MV
    Arzneimittelforschung; 1996 Jan; 46(1):41-6. PubMed ID: 8821516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
    Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
    Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
    Singh KP; Periyandavar I; Rajadhyaksha GC; Jayaram S; Mishra AB; Kinagi S; Sharma A; Baliga VP
    J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
    Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
    Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.